Cancer Research Prevention Award  Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 8221, October 15, 2008. doi: 10.1158/0008-5472.CAN-08-0561
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bartolomé, R. A.
Right arrow Articles by Teixidó, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bartolomé, R. A.
Right arrow Articles by Teixidó, J.

Cell, Tumor, and Stem Cell Biology

Activated G{alpha}13 Impairs Cell Invasiveness through p190RhoGAP-Mediated Inhibition of RhoA Activity

Rubén A. Bartolomé, Natalia Wright, Isabel Molina-Ortiz, Francisco J. Sánchez-Luque and Joaquin Teixidó

Department of Cellular and Molecular Physiopathology, Centro de Investigaciones Biológicas (CSIC), Madrid, Spain

Requests for reprints: Joaquin Teixidó, Centro de Investigaciones Biológicas, Department of Cellular and Molecular Physiopathology, Ramiro de Maeztu 9, 28040 Madrid, Spain. Phone: 34-91-8373112; Fax: 34-91-5360432; E-mail: joaquint{at}cib.csic.es.

Key Words: Chemokines • Melanoma • Invasion • RhoGTPases • Metastasis

The GTPase RhoA is a downstream target of heterotrimeric G13 proteins and plays key roles in cell migration and invasion. Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient G{alpha}13 form (G{alpha}13QL) or lysophosphatidylcholine (LPC)-promoted signaling through G{alpha}13-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA. Melanoma cells expressing G{alpha}13QL or cells stimulated with LPC displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G{alpha}13 target that is responsible for these inhibitory responses. In addition, defective stress fiber assembly and reduced migration speed underlay inefficient invasion of G{alpha}13QL melanoma cells. Importantly, G{alpha}13QL expression in melanoma cells led to impairment in lung metastasis associated with prolonged survival in SCID mice. The data indicate that G{alpha}13-dependent downstream effects on RhoA activation and invasion tightly depend on cell type–specific GAP activities and that G{alpha}13-p190RhoGAP signaling might represent a potential target for intervention in melanoma metastasis. [Cancer Res 2008;68(20):8221–30]




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
I. Molina-Ortiz, R. A. Bartolome, P. Hernandez-Varas, G. P. Colo, and J. Teixido
Overexpression of E-cadherin on Melanoma Cells Inhibits Chemokine-promoted Invasion Involving p190RhoGAP/p120ctn-dependent Inactivation of RhoA
J. Biol. Chem., May 29, 2009; 284(22): 15147 - 15157.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.